Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

IF 2.3 Q3 PHARMACOLOGY & PHARMACY

Scientia Pharmaceutica Pub Date : 2023-12-25 DOI:10.3390/scipharm92010002

Ana Marcela Arrieta Gómez, María Antonia Díaz-Mendoza, Yesit Bello Lemus, Grethel León-Mejía, Martha Lucia Ruiz Benitez

{"title":"Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis","authors":"Ana Marcela Arrieta Gómez, María Antonia Díaz-Mendoza, Yesit Bello Lemus, Grethel León-Mejía, Martha Lucia Ruiz Benitez","doi":"10.3390/scipharm92010002","DOIUrl":null,"url":null,"abstract":"The aim of this study was to establish the relationship between different polymorphisms in drug transporter and metabolizer genes and resistance to imatinib in chronic myeloid leukemia (CML). For this purpose, an exhaustive search was carried out in the Scopus, Web of Science, and PubMed databases using different combinations of keywords with different inclusion and exclusion criteria. The meta-analysis included nine studies that met the established criteria. The results of the study showed that the polymorphic variants AG and GG of CYP3A5*3 are associated with response to treatment, presenting a significantly lower risk with resistance to imatinib. Likewise, the variants T1236C and G2677T/A of the ABCB1 gene show a significant association with treatment efficacy. In addition, the genetic polymorphism 1236T, homozygous CC of the MDR1 gene, significantly influences the increased risk of cytogenetic relapse and the polymorphic variant 361G>A GA of the SLCO1A2 gene significantly affects the complete molecular response.","PeriodicalId":21601,"journal":{"name":"Scientia Pharmaceutica","volume":"6 3","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scientia Pharmaceutica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/scipharm92010002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of this study was to establish the relationship between different polymorphisms in drug transporter and metabolizer genes and resistance to imatinib in chronic myeloid leukemia (CML). For this purpose, an exhaustive search was carried out in the Scopus, Web of Science, and PubMed databases using different combinations of keywords with different inclusion and exclusion criteria. The meta-analysis included nine studies that met the established criteria. The results of the study showed that the polymorphic variants AG and GG of CYP3A5*3 are associated with response to treatment, presenting a significantly lower risk with resistance to imatinib. Likewise, the variants T1236C and G2677T/A of the ABCB1 gene show a significant association with treatment efficacy. In addition, the genetic polymorphism 1236T, homozygous CC of the MDR1 gene, significantly influences the increased risk of cytogenetic relapse and the polymorphic variant 361G>A GA of the SLCO1A2 gene significantly affects the complete molecular response.

查看原文本刊更多论文

药物转运体和代谢基因的多态性与慢性粒细胞白血病患者对伊马替尼的耐药性有关：系统回顾与元分析

本研究旨在确定药物转运体和代谢基因的不同多态性与慢性髓性白血病（CML）患者对伊马替尼耐药性之间的关系。为此，我们在 Scopus、Web of Science 和 PubMed 数据库中使用不同的关键词组合和不同的纳入和排除标准进行了详尽的检索。荟萃分析包括九项符合既定标准的研究。研究结果表明，CYP3A5*3的多态变异AG和GG与治疗反应有关，对伊马替尼耐药的风险明显较低。同样，ABCB1 基因的变异体 T1236C 和 G2677T/A 与疗效也有显著关联。此外，MDR1 基因的同源 CC 基因多态性 1236T 显著影响细胞遗传学复发风险的增加，SLCO1A2 基因的多态性变异 361G>A GA 显著影响完全分子反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Scientia Pharmaceutica Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

4.60

自引率

4.00%

发文量

审稿时长

10 weeks